Boundless Bio has announced a strategic portfolio prioritization aimed at optimizing its oncology programs, particularly focusing on the combination therapy of BBI-355 and BBI-825, alongside a new ...
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...
COPENHAGEN, Denmark; December 29, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s ...
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...
Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready ...
Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback